To verify the role of NEIL3 in therapeutic sensitivity, we constructed NEIL3 knockdown cell lines via transfecting two small interfering RNAs into lymph node carcinoma of the prostate (LNcap), Duke University 145 (DU145) and prostate cancer cell line (PC3) cells. This evidence concerns the gene NEIL3 and prostate carcinoma.